Ionis to present at upcoming investor conferences
Ionis Pharmaceuticals (NASDAQ: IONS) has announced its participation in six major healthcare investor conferences throughout November and December 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ionis Pharmaceuticals (NASDAQ: IONS) has announced its participation in six major healthcare investor conferences throughout November and December 2024. The company's management will engage in fireside chats at events including Guggenheim's Inaugural Healthcare Conference, UBS Global Healthcare Conference, Stifel Healthcare Conference, Jefferies London Healthcare Conference, Citi's Global Healthcare Conference, and Piper Sandler Annual Healthcare Conference. Live webcasts will be available on the Ionis website's Investors & Media section, with replays accessible within 48 hours and archived for a time.
Details
News Market Reaction – IONS
The recorded move for IONS in the trading session of this news was -1.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Guggenheim's Inaugural Healthcare Conference on Wednesday, November 13, 2024
- UBS Global Healthcare Conference on Wednesday, November 13, 2024
- Stifel 2024 Healthcare Conference on Monday, November 18, 2024
- Jefferies London Healthcare Conference on Wednesday, November 20, 2024
- Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024
- Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024
A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.
About Ionis Pharmaceuticals
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.
To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.
Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. – ir@ionis.com – 760-603-2331
Ionis Pharmaceuticals Media Contact:
Hayley Soffer – media@ionis.com – 760-603-4679
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-upcoming-investor-conferences-302297951.html
SOURCE Ionis Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.